Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis

Evidence is accumulating that growth hormone (GH) protects against the development of steatosis and progression of non-alcoholic fatty liver disease (NAFLD). GH may control steatosis indirectly by altering systemic insulin sensitivity and substrate delivery to the liver and/or by the direct actions of GH on hepatocyte function.

Source: Metabolism - Clinical and Experimental - May 12, 2023 Category: Biomedical Science Authors: Mari C. V ázquez-Borrego, Mercedes del Río-Moreno, Maxim Pyatkov, André Sarmento-Cabral, Mariyah Mahmood, Natalie Pelke, Magdalena Wnek, Jose Cordoba-Chacon, David J. Waxman, Michelle A. Puchowicz, Owen P. McGuinness, Rhonda D. Kineman Source Type: research